1. Indications and Usage
\nComplicated Intra-Abdominal Infections (cIAI):
\nIndicated for the treatment of adult patients with cIAI caused by susceptible isolates of Escherichia coli, Klebsiella pneumoniae, Klebsiella aerogenes, Enterobacter cloacae complex, Citrobacter freundiicomplex, Serratia marcescens, and Proteus mirabilis.
\nHospital-Acquired Pneumonia (HAP):
\nIndicated for the treatment of adult patients with HAP, including Ventilator-Associated Pneumonia (VAP), caused by susceptible isolates of K. pneumoniae, Enterobacter cloacae complex, E. coli, S. marcescens, K. aerogenes, Stenotrophomonas maltophilia, P. mirabilis, and Morganella morganii.
\n2. Dosage and Administration
\nRecommended Dosage (Adults with eCrCL > 50 mL\/min):
\nDose: Aztreonam 1.5 g \/ Avibactam 0.5 g (or Aztreonam 2 g \/ Avibactam 0.67 g).
\nFrequency: Every 6 hours.
\nInfusion Time: Administer as a 3-hour intravenous infusion.
\nRenal Impairment:
\nDosage adjustment is required for patients with an estimated creatinine clearance (eCrCL) \u2264 50 mL\/min.
\nAdministration:
\nAdminister via intravenous infusion only. Do not admix with other drugs.
\n3. Mechanism of Action
\nAztreonam (Antibiotic):
\nA monobactam that binds to Penicillin-Binding Proteins (PBPs), inhibiting bacterial cell wall synthesis and causing cell lysis. It is stable against most \u03b2-lactamases, including Metallo-\u03b2-lactamases (MBLs).
\nAvibactam (Inhibitor):
\nA non-\u03b2-lactam \u03b2-lactamase inhibitor that inhibits Ambler Class A (e.g., KPC, ESBLs), Class C (AmpC), and certain Class D (e.g., OXA-48) \u03b2-lactamases, thereby protecting aztreonam from degradation.
\n4. Safety and Warnings
\nHypersensitivity Reactions:
\nHypersensitivity reactions may occur.
\nSeizures:
\nNeurotoxicity, including seizures, may occur, particularly in patients with renal impairment or those receiving high doses.
\nLaboratory Interference:
\nAvibactam may cause false-positive results in certain urine glucose tests (e.g., Clinitest).
\n5. Adverse Reactions
\nMost Common:
\nAnemia (6.9%), diarrhea (6.2%), increased alanine aminotransferase (ALT) (6.2%), and increased aspartate aminotransferase (AST) (5.2%).
\n6. Drug Interactions
\nProbenecid:
\nProbenecid may inhibit the renal excretion of aztreonam and avibactam, leading to increased exposure. Concurrent use is not recommended.
\n7. Pharmaceutical Information
\nChemical Composition:
\nActive Ingredients: Aztreonam and Avibactam Sodium.
\nStorage:
\nStore below 30\u00b0C. Protect from light.<\/p>\n","protected":false},"excerpt":{"rendered":"
Brand Name: \u601d\u798f\u8bfa\u00ae(Emblaveo\u00ae)
\nGeneric Name: Aztreonam and Avibactam Sodium
\nStrength: Each vial total 2.0g (Aztreonam 1.5g + Avibactam 0.5g), 10 vials per box
\nManufacturer: Pfizer Inc.
\nMarketing Authorization Holder: Pfizer Investment Co., Ltd.
\nApproval Date in China: June 24, 2025
\nRegistration Number: \u56fd\u836f\u51c6\u5b57 HJ20250078
\nStorage: Sealed, protected from light, stored at 2\u2103 ~ 8\u2103, keep out of reach of children<\/p>\n
Price&Cost:Contact Us now for the best price of Aztreonam and Avibactam Sodium(Emblaveo\uff09<\/p>\n","protected":false},"featured_media":3284,"comment_status":"open","ping_status":"closed","template":"","meta":[],"product_brand":[81],"product_cat":[25],"product_tag":[],"class_list":["post-3283","product","type-product","status-publish","has-post-thumbnail","product_brand-pfizer","product_cat-injection","first","instock","shipping-taxable","product-type-simple"],"yoast_head":"\n